Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Linde PLC — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Linde PLC trades at $490.32 (market cap $227.01B). The key difference: Linde PLC is far larger — about 24.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LIN | |
|---|---|---|
Market Cap | $9.39B | $227.01B |
Sector | Health | Basic Materials |
52-Week High | $356.25 | $546.64 |
52-Week Low | $241.71 | $389.38 |
Enterprise Value | $9.14B | $250.13B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Linde (LIN) trades at $490.53, up 0.11% on the day, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.50 surpassing expectations. Revenue grew to $34.0B in 2025, with a net income margin of 20.43%. Analysts maintain a strong buy consensus with a $553.60 price target, highlighting robust profitability and dividend growth.
Outlook remains positive due to earnings momentum and sustainability leadership, but risks include elevated valuation multiples and rising debt-to-asset ratio. The stock offers steady income with a $1.60 dividend, yet technical weakness near support at $489 warrants caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
